TimesSquare Capital Management LLC Purchases New Position in Humana Inc. (NYSE:HUM)

TimesSquare Capital Management LLC bought a new stake in Humana Inc. (NYSE:HUM - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 146,532 shares of the insurance provider's stock, valued at approximately $46,413,000. TimesSquare Capital Management LLC owned 0.12% of Humana as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. lifted its position in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider's stock worth $28,000 after acquiring an additional 39 shares during the period. Creative Financial Designs Inc. ADV grew its position in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock valued at $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. acquired a new position in Humana in the 3rd quarter valued at $29,000. Hantz Financial Services Inc. acquired a new position in Humana in the 2nd quarter valued at $35,000. Finally, Family Firm Inc. purchased a new position in Humana during the 2nd quarter worth $37,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HUM. TD Cowen boosted their price target on shares of Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a research note on Monday, November 4th. Leerink Partnrs cut Humana from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 2nd. Jefferies Financial Group cut Humana from a "buy" rating to a "hold" rating and reduced their price target for the company from $519.00 to $253.00 in a report on Monday, October 7th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Finally, KeyCorp began coverage on Humana in a report on Friday, October 11th. They issued a "sector weight" rating for the company. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $315.86.

Humana Trading Up 0.1 %

NYSE:HUM traded up $0.36 during mid-day trading on Friday, reaching $288.12. The company's stock had a trading volume of 1,691,681 shares, compared to its average volume of 2,587,340. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market cap of $34.69 billion, a P/E ratio of 25.52, a P/E/G ratio of 2.28 and a beta of 0.52. The company's fifty day simple moving average is $289.38 and its two-hundred day simple moving average is $332.70. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $527.18.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion for the quarter, compared to analysts' expectations of $28.66 billion. On average, equities analysts predict that Humana Inc. will post 15.83 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Tuesday, December 31st. Humana's payout ratio is currently 31.36%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.